FindTrial
Sign In

JZP-110

DRUG7 trials

Sponsors

Jazz Pharmaceuticals

Conditions

Excessive SleepinessNarcolepsyObstructive Sleep ApneaParkinson Disease

Phase 2

Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
CompletedNCT02806908
Jazz PharmaceuticalsExcessive Sleepiness, Narcolepsy
Start: 2016-06-30End: 2019-05-19Updated: 2021-01-13
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
CompletedNCT02806895
Jazz PharmaceuticalsExcessive Sleepiness, Obstructive Sleep Apnea
Start: 2016-07-05End: 2019-05-28Updated: 2021-01-14
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
CompletedNCT03037203
Jazz PharmaceuticalsExcessive Sleepiness, Parkinson Disease
Start: 2017-01-31End: 2018-08-31Updated: 2020-01-09

Phase 3

Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA
CompletedNCT02348619
Jazz PharmaceuticalsObstructive Sleep Apnea
Start: 2015-05-31End: 2016-11-30Updated: 2019-09-09
Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy
CompletedNCT02348593
Jazz PharmaceuticalsNarcolepsy
Start: 2015-05-31End: 2017-02-28Updated: 2019-07-23
Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA
CompletedNCT02348606
Jazz PharmaceuticalsObstructive Sleep Apnea
Start: 2015-05-31End: 2016-12-31Updated: 2019-07-23
A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA
CompletedNCT02348632
Jazz PharmaceuticalsNarcolepsy, Obstructive Sleep Apnea
Start: 2015-05-31End: 2017-12-31Updated: 2019-06-25

Related Papers

Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions.
2022-12-10
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
2022-01-017 citations
Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
2021-10-0115 citations
Effects of solriamfetol on real-world driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
2021-04-161 citations
Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
2021-04-015 citations
Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
2021-02-2227 citations
Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea
Sleep And Breathing2021-01-0423 citations
Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy
Journal of Clinical Sleep Medicine2020-11-1118 citations
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
2020-07-0113 citations
Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial
Annals of the American Thoracic Society2020-04-3040 citations
Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
2019-12-0424 citations
Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea
SLEEP2019-11-06246 citations
A randomized study of solriamfetol for excessive sleepiness in narcolepsy
Annals of Neurology2019-01-29318 citations
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial
American Journal of Respiratory and Critical Care Medicine2018-12-06305 citations
Solriamfetol for the Treatment of Excessive Sleepiness in OSA
CHEST Journal2018-11-2280 citations